高分辨率CT对颞部疾病的检查价值

目的：探讨高分辨率CT（HRCT）对颞部疾病的检查价值。方法：对43例颞部疾病患者行常规CT和高分辨率CT（HRCT）检查所获图像对比分析，并讨论HRCT的检查技术和图像后处理。结果：HRCT对病变的显示率及病变引起骨质破坏的程度，病变边缘，轮廓的显示均明显优于常规CT，尤其能清楚显示常规CT难以显示的中耳及内耳的细微结构，结论：高分辨率CT是颞部疾病的首选检查方法，使用高分辨率CT对颞部疾病的检查给临床提供更多，更准确的诊断信息。     

艾滋病142例临床表现分析

目的艾滋病(AIDS),是严重危害人类健康的疾病,临床上症状多变,应提高对AIDS的认识。现将作者在西非工作期间收治的142例AIDS病例的临床表现作一介绍。方法病例均为当地黑人居民,男性89例,女性53例,年龄14～45岁,平均年龄27.65岁。用酶联免疫吸附法和快速法检测患者血清中HIV—1和 HIV—2抗体。结果 HIV—1型25例(35.00％);HIV-2型74例(52.11％);混合型32例(22.53％)。临床表现为脑膜脑炎或脑炎7例(4.93％);肺型27例(19.01％);胃肠道感染84例(59.15％):包括急性48例(33.80％),慢性24例(16.90％),急腹症12例(8.45％);皮肤粘膜损害18例(12.68％):卡波齐肉瘤6例(4.23％),带状疱疹2例(1.41％),皮炎10例(7.04％),病死率19.72％(28/142)。其传播途径以性传播为主,高达78.87％(112/142),其次是密切生活接触,未发现吸毒或输血者。结论艾滋病病死率高,病情复杂,且目前尚无特效药物,必须引起医护人员高度重视。     

HPLC法测定小柴胡颗粒剂中黄芩苷的含量

目的 :建立小柴胡颗粒剂中黄芩苷的含量测定方法。方法 :采用反相高效液相色谱法。色谱柱 :Inertsil ODS- 3(5 μm,4 .6× 2 5 0 mm)柱 ;流动相 :甲醇 -水 -磷酸 (45∶ 5 5∶ 0 .2 ) ;检测波长 :315 nm。结果 :黄芩苷在 0 .2 4 2 9～ 1.2 14 4 μg/ml范围内呈现良好的线性关系 (r=0 .9999) ,回收率 10 0 .0 % ,RSD=0 .96 %。结论 :本法可用于测定小柴胡颗粒剂中黄芩苷的含量。     

PPD为丝裂源作淋巴细胞转化试验对结核性胸膜炎的诊断价值

以结核菌素纯蛋白衍生物(PPD)为丝裂源作淋巴细胞转化试验,检测结核性(17例)和非结核性(14例)胸膜炎患者的外周血淋巴细胞(PBL)和胸腔积液淋巴细胞(PEL)对PPD 的反应性。结果显示:结核性胸膜炎患者无论PPD 皮试是阳性还是阴性,其PEL 的PPD 刺激指数(PPD-SI)都显著高于PBL(P 分别<0.001与<0.01);结核性PEL 的PPD-SI 显著高于非结核性PEL(P<0.001)。提示PPD 胸腔积液淋巴细胞转化试验可作为诊断结核性胸膜炎的有效方法。     

胫骨骨条植骨结合多根克氏针内固定治疗股骨颈骨折

从1985年起,应用胫骨骨条植骨结合多根克氏针内固定治疗股骨颈骨折21例,经随访7个月—48个月,优17例、良3例、差1例。通过临床观察,用自体胫骨骨条植骨提供活的骨细胞及诱导成骨,能促进加速骨折愈合。本手术方法简单、安全     

Prevention of Bone Loss by Clodronate in Early Postmenopausal Women with Vertebral Osteopenia: A Dose-Finding Study

This double-masked, placebo-controlled study was undertaken to determine the efficacy and safety of oral clodronate in the prevention of bone loss in early postmenopausal women with vertebral osteopenia. Altogether 610 women with a mean age of 53 years were recruited for the study. They were 1–5 years postmenopausal and their lumbar spine bone mineral density (BMD) was at least 1 standard deviation below the mean of premenopausal women (T-score ≤−1). The subjects were randomized into five study groups to receive either placebo, clodronate 65 mg, 400 mg or 800 mg daily, or intermittent clodronate in 3 month cycles with 400 mg daily for 15 days followed with no treatment for 75 days for 3 years. One hundred and eighty-seven of 509 women who completed the primary study continued in the extension study of 2 years in which previous placebo users were switched to clodronate 800 mg daily, while previous users of 400 mg or 800 mg of clodronate used either placebo or 800 mg of clodronate daily. In the primary study clodronate was administered in the evening, and in the extension 1 h before breakfast on an empty stomach. In the primary study mean changes in lumbar spine BMD were −3.4% in the placebo group and +0.4% in 800 mg clodronate group [difference between groups at 3 years 3.8% (95% CI 2.7% to 4.9%, p<0.0001)], and in the trochanter area BMD −1.1% in the placebo group, and + 0.4% in the 800 mg clodronate group [difference between groups at 3 years 1.5% (95% CI 0.05% to 2.9%)]. During the extension study mean changes in lumbar spine BMD were +1.5% in the clodronate group and −0.2 % in the placebo group [difference between groups 1.7% (CI 0.4% to 3.0%, p = 0.010)] and in trochanter BMD were +2.5% in the clodronate group and no change in the placebo group [difference between groups 2.1% (CI 0.3% to 3.9%, p = 0.007)]. No statistically significant differences between the placebo and 800 mg clodronate groups were found in the femoral neck BMD. In the primary study the urinary excretion of type I collagen aminoterminal telopeptide (NTX) decreased by 44% (p<0.0001 compared with placebo) and that of deoxypyridinoline by 18% (p<0.0001) in the clodronate 800 mg group. In the extension study urinary NTX decreased by 51% (p<0.0001) in those who were switched to 800 mg of clodronate and increased by 67% (p<0.0001) in those who stopped using that dose. There was no difference in the frequency of gastrointestinal complaints between clodronate- and placebo-treated patients in the primary study, but they were more common among women who received clodronate in the extension phase. Clodronate in daily doses of 400–800 mg caused a slight elevation of aminotransferase levels, usually within the reference range. In bone biopsies no defect in mineralization was found. In conclusion, clodronate in a daily dose of 800 mg prevents early postmenopausal bone loss at the sites of the skeleton in which cancellous bone predominates. It effectively reduces bone resorption and bone turnover rate. Antifracture efficacy of clodronate remains to be established by prospective, placebo-controlled trials. Received: 4 March 2002 / Accepted: 9 July 2002     

膨润土对药用混悬液助悬性能的考察

本文报道了无机胶体膨润土(Bentonite)作为助悬剂在炉甘石洗剂中的应用,并与有机助悬剂及另一种无机胶体XVT—M进行比较,显示了其优异的助悬性能。